Patients with B-cell ALL bearing the same KMT2A::AFF1 translocations have distinct enhancers that are important for cancer maintenance and influence outcome. Smith et al discovered that in samples of patients with ALL with the same KMT2A::AFF1 translocations, patient-specific enhancer utilization drives distinct transcriptional profiles. KMT2A::AFF1 may engage with unknown accessory proteins and cofactors among patients to modulate enhancer activity. These unique interactions influence gene expression distinctly among patients and are associated with patient survival outcomes. This figure was created with BioRender.com. Lin, S. (2025) https://BioRender.com/chbvwbf.

Patients with B-cell ALL bearing the same KMT2A::AFF1 translocations have distinct enhancers that are important for cancer maintenance and influence outcome. Smith et al discovered that in samples of patients with ALL with the same KMT2A::AFF1 translocations, patient-specific enhancer utilization drives distinct transcriptional profiles. KMT2A::AFF1 may engage with unknown accessory proteins and cofactors among patients to modulate enhancer activity. These unique interactions influence gene expression distinctly among patients and are associated with patient survival outcomes. This figure was created with BioRender.com. Lin, S. (2025) https://BioRender.com/chbvwbf.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal